Nam Joong Kim

Nam Joong Kim

Auto-generated profile, based on publicly available information

Nam Joong Kim

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
EKEu Suk Kim
Eu Suk Kim
BCBum Sik Chin
Bum Sik Chin
CKChang Kyung Kang
Chang Kyung Kang
NKNam Joong Kim
Nam Joong Kim
KYKang Yumin
Kang Yumin
OCon behalf of the Korea National Committee for Clinical Management of COVID-19
on behalf of the Korea National Committee for Clinical Management of COVID-19
Kim ES, et al. J Korean Med Sci. 2020 Feb;35(13):e142. https://doi.org/10.3346/jkms.2020.35.e142

1 January 2020 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
WPWan Beom Park
Wan Beom Park
NKNak-Jung Kwon
Nak-Jung Kwon
SCSu-Jin Choi
Su-Jin Choi
CKChang Kyung Kang
Chang Kyung Kang
PCPyoeng Gyun Choe
Pyoeng Gyun Choe
MOMyoung-Don Oh
Myoung-Don Oh
Park WB, et al. J Korean Med Sci. 2019 Dec;35(7):e84. https://doi.org/10.3346/jkms.2020.35.e84

1 January 2016 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
EKEu Suk Kim
Eu Suk Kim
PCPyoeng Gyun Choe
Pyoeng Gyun Choe
WPWan Beom Park
Wan Beom Park
HOHong Sang Oh
Hong Sang Oh
EKEun Jung Kim
Eun Jung Kim
MOMyoung-Don Oh
Myoung-Don Oh
Kim ES, et al. J Korean Med Sci. 2016 Nov;31(11):1717-1725. https://doi.org/10.3346/jkms.2016.31.11.1717

13 October 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
KBKelly L. Bolton
Kelly L. Bolton
YKYoungil Koh
Youngil Koh
MFMichael B. Foote
Michael B. Foote
HIHogune Im
Hogune Im
JJJustin Jee
Justin Jee
AZAhmet Zehir
Ahmet Zehir
Acquired somatic mutations in hematopoietic stem and progenitor cells (clonal hematopoiesis or CH) are associated with advanced age, increased risk of cardiovascular and malignant diseases, and decreased overall survival. These adverse sequelae may be mediated by altered inflammatory profiles observed in patients with CH. A pro-inflammatory immunologic profile is also associated with worse outcomes of certain infections, including SARS-CoV-2 and its associated disease Covid-19. Whether CH predisposes to severe Covid-19 or other infections is unknown. Among 525 individuals with Covid-19 from Memorial Sloan Kettering (MSK) and the Korean Clonal Hematopoiesis (KoCH) consortia, we show that CH is associated with severe Covid-19 outcomes (OR = 1.85, 95%=1.15–2.99, p = 0.01), in particular CH characterized by non-cancer driver mutations (OR = 2.01, 95% CI = 1.15–3.50, p = 0.01). We further explore the relationship between CH and risk of other infections in 14,211 solid tumor patients at MSK. CH is significantly associated with risk of Clostridium Difficile (HR = 2.01, 95% CI: 1.22–3.30, p = 6×10−3) and Streptococcus/Enterococcus infections (HR = 1.56, 95% CI = 1.15–2.13, p = 5×10−3). These findings suggest a relationship between CH and risk of severe infections that warrants further investigation.

24 July 2024 in Nature
Verified
Journal Article
Closed access
PDF file
TKTae Hyun Kim
Tae Hyun Kim
JKJunwon Kang
Junwon Kang
HJHaewook Jang
Haewook Jang
HJHyelyn Joo
Hyelyn Joo
GLGi Yoon Lee
Gi Yoon Lee
SKSunghoon Kwon
Sunghoon Kwon

27 January 2021 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
SKSang Il Kim
Sang Il Kim
JNJinsung Noh
Jinsung Noh
SKSujeong Kim
Sujeong Kim
YCYounggeun Choi
Younggeun Choi
DYDuck-Kyun Yoo
Duck-Kyun Yoo
JCJunho Chung
Junho Chung
Stereotypic antibody clonotypes exist in healthy individuals and may provide protective immunity against viral infections by neutralization. We observed that 13 out of 17 patients with COVID-19 had stereotypic variable heavy chain (VH) antibody clonotypes directed against the receptor-binding domain (RBD) of SARS-CoV-2 spike protein. These antibody clonotypes were comprised of immunoglobulin heavy variable (IGHV)3-53 or IGHV3-66 and immunoglobulin heavy joining (IGHJ)6 genes. These clonotypes included IgM, IgG3, IgG1, IgA1, IgG2, and IgA2 subtypes and had minimal somatic mutations, which suggested swift class switching after SARS-CoV-2 infection. The different immunoglobulin heavy variable chains were paired with diverse light chains resulting in binding to the RBD of SARS-CoV-2 spike protein. Human antibodies specific for the RBD can neutralize SARS-CoV-2 by inhibiting entry into host cells. We observed that one of these stereotypic neutralizing antibodies could inhibit viral replication in vitro using a clinical isolate of SARS-CoV-2. We also found that these VH clonotypes existed in six out of 10 healthy individuals, with IgM isotypes predominating. These findings suggest that stereotypic clonotypes can develop de novo from naïve B cells and not from memory B cells established from prior exposure to similar viruses. The expeditious and stereotypic expansion of these clonotypes may have occurred in patients infected with SARS-CoV-2 because they were already present.